TScan Therapeutics’ cover photo
TScan Therapeutics

TScan Therapeutics

Biotechnology Research

Waltham, Massachusetts 9,158 followers

Unleash Immunity

About us

TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. TScan Therapeutics is a fully integrated, next-generation TCR-T cell therapy company. Founded in 2018, TScan’s platform was developed by Stephen Elledge, Ph.D., and Tomasz Kula, Ph.D., at Brigham and Women’s Hospital and Harvard Medical School. TScan’s transformative platform enables rapid discovery of TCRs and targets for engineered T cell therapy. This technology is extremely versatile and is applicable across multiple therapeutic areas beyond cancers, including autoimmune disorders and infectious diseases.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Waltham, Massachusetts
Type
Public Company
Founded
2018
Specialties
TCR-T Cell Therapy

Locations

Employees at TScan Therapeutics

Updates

Similar pages

Browse jobs

Funding